Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, announced its $365 million Series D financing, bringing its post-money...
Avacta Therapeutics, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces the initiation...
